Tumor targeting of innate and adaptive immunity by the adoptive cell transfer of engineered T lymphocytes co-expressing iNKT and tumor-specific MHC-I TCRs

Documenti analoghi

• iNKT/CD1d-antitumor immunotherapy significantly increases the efficacy of therapeutic CpG/peptide-based cancer vaccine
  di: Corgnac, Stéphanie, et al.
  Pubblicazione: (2014)
• CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses
  di: Corgnac, Stéphanie, et al.
  Pubblicazione: (2012)
• ID2 collaborates with ID3 to suppress iNKT and innate-like tumors(1)
  di: Li, Jia, et al.
  Pubblicazione: (2017)
• TSC1 promotes iNKT cell anergy and inhibits iNKT cell-mediated anti-tumor immunity
  di: Wu, Jinhong, et al.
  Pubblicazione: (2014)
• Transcription factor Bcl11b sustains iNKT1 and iNKT2 cell programs, restricts iNKT17 cell program, and governs iNKT cell survival
  di: Uddin, Mohammad Nizam, et al.
  Pubblicazione: (2016)